Neurofibromatosis Treatment Market – Global Industry Analysis, Segmentation and Forecast (2023-2029)

Global Neurofibromatosis Treatment Market value is projected to reach US$ 27.06 Bn at the end of the forecast period and it is expected to grow at the CAGR of 13.3%.

Neurofibromatosis Treatment Market Overview & Dynamics:

Neurofibromatosis is a group of genetic disorders, which forms tumor on the nerve tissue. These tumors develop anywhere in the nervous system including brain, spinal cord and nerves. There are three types of neurofibromatosis: neurofibromatosis 1 (NF1), neurofibromatosis 2 (NF2) and Schwannomatosis. NF1 is usually diagnosed in childhood, while NF2 and Schwannomatosis are usually diagnosed in early adulthood. NF1 occurs in approximately one out of every 3,500 births, NF2 occurs in approximately one out of every 40,000 births and Schwannomatosis occurs an estimated one out of every 40,000 births.Neurofibromatosis Treatment MarketTo know about the Research Methodology :- Request Free Sample Report

Ongoing development of novel therapies for treating neurofibromatosis drives the market growth.

Increasing R&D activities and focus of major players for the development of novel therapies for treatment is expected to drive the market. Also, the dynamics of the neurofibromatosis market is expected to change during forecast period owing to the improvement in the diagnosis methodologies, increasing awareness of the disease, rise in healthcare expenditure will also contribute to stimulate the market growth. The Children’s Tumor Foundation (CTF) has provided support to the NF community, including efforts to advance research as well as public education and patient support. In 2007, the CTF invested $4 million to launch the Neurofibromatosis Preclinical Consortium (NFPC) to test candidate drug therapies in NF1 and NF2 models. The report covers the detailed analysis of global Neurofibromatosis Treatment industry with the classifications of the market based on type, treatment and end-users. Analysis of past market dynamics from 2018 to 2022 is given in the report, which will help readers to benchmark the past trends with current market scenarios with the key players contribution in it. The report has profiled eighteen key players in the market from different regions. However, report has considered all market leaders, followers and new entrants with investors while analyzing the market and estimation the size of the same. Increasing R&D activities in each region are different and focus is given on the regional impact on the availability of advanced technology and new product launches are analyzed and report has come up with recommendations for future hot spot in APAC region.

Global Neurofibromatosis Treatment Market Segment Analysis:

The global Neurofibromatosis Treatment market is segmented based on the type, treatment and end-users. The type segment is sub-segmented as NF1, NF2 and Schwannomatosis. Therapeutic development in NF1 has been tumour-specific, due to the substantial heterogeneity of the development and behaviour of NF1-associated tumor across and within patients. Understanding of the pathogenesis and molecular landscape of the NF1-associated tumor has advanced dramatically in recent years. This advancement, along with the continued collaborative approaches across the research community, has fuelled therapeutic development efforts against many of the NF1 manifestations. According to the Neurofibromatosis Clinics Association, NF2 is a rarer type, occurring in 1:25,000 people worldwide. Based on the treatment segment, it is classified into surgery, focused radiation therapy and chemotherapy. Most commonly used are the surgeries for the removal of tumor. Though surgery is the mainstay treatment for tumor which are less than 3 cm, these approaches have proved less effective in NF2, which includes high rate of complications like facial nerve weakness, hearing loss and headache. Moreover, there are growing concerns about utilizing radiation therapy in NF2 due to risk of late malignant transformation. Radiation therapy is mainly reserved for the treatment of life threatening tumor in Schwannomatosis. On April 10, 2021, the Food and Drug Administration approved selumetinib (KOSELUGO, AstraZeneca) for paediatric patients, 2 years of age and older, with neurofibromatosis type 1 (NF1) who have symptomatic, inoperable plexiform neurofibromas (PN). Selumetinib, a kinase inhibitor, is the first therapy approved for paediatric patients who have this debilitating, and often disfiguring, rare disease.

Regional Insights:

North America is anticipated to witness a lucrative market growth in terms of revenue, by registering a CAGR of xx% during forecast period The ongoing research methodologies for the development of newer treatment protocols in the region helps in shaping the overall market growth. The research work done by National Institute on Neurological Disorders and Stroke (NINDS) is focused on seeking the fundamental knowledge about the brain and nervous system to reduce the burden on neurological disease. Ongoing NINDS-sponsored research continues to discover additional genes and molecular pathways that may play a role in NF-related tumor suppression or growth. Asia Pacific is expected as the fastest growing region during forecast period at a CAGR of xx%. APAC is experiencing fastest growth as the population increasing rapidly, rising consumer awareness, favorable government policies and modernization in medical infrastructure essentially in developing nations like India, China and Japan. Despite of these trends, in some developing regions like India to mention, cases of psychological and emotional trauma are prevailing due to cosmetic deformity caused by NF. The report also helps in understanding Global Neurofibromatosis Treatment Market dynamics, structure by analyzing the market segments and project the Global Neurofibromatosis Treatment Market size. Clear representation of competitive analysis of key players by product, price, financial position, product portfolio, growth strategies, and regional presence in the Global Neurofibromatosis Treatment Market make the report investor’s guide.

Global Neurofibromatosis Treatment Market Scope: Inquire before Buying

Global Neurofibromatosis Treatment Market
Report Coverage Details
Base Year: 2022 Forecast Period: 2023-2029
Historical Data: 2018 to 2022 Market Size in 2022: US $ 11.29 Bn.
Forecast Period 2023 to 2029 CAGR: 13.3% Market Size in 2029: US $ 27.06 Bn.
Segments Covered: by Type Neurofibromatosis 1 (NF1) Neurofibromatosis 2 (NF2) Schwannomatosis
by Treatment Surgery Focused radiation Chemotherapy
by End-Users Hospitals Clinics Others

Neurofibromatosis Treatment Market, by Region

Asia Pacific (China, South Korea, Japan, India, Australia, Indonesia, Malaysia, Vietnam, Taiwan, Bangladesh, Pakistan and Rest of APAC) Europe (UK, France, Germany, Italy, Spain, Sweden, Austria and Rest of Europe) North America (United States, Canada and Mexico) Middle East and Africa (South Africa, GCC, Egypt, Nigeria and Rest of ME&A) South America (Brazil, Argentina Rest of South America)

Global Neurofibromatosis Treatment Market Key Players

1. Erasmus Medical Center 2. GL Pharm Tech Corporation 3. University of Alabama at Birmingham 4. Assistance Publique - Hôpitaux de Paris 5. Indiana University 6. TATA Memorial Hospital (India) 7. Apollo Hospitals (India) 8. BLK Super Specialty Hospital 9. Fortis Hospitals 10. Texas Neurofibromatosis Foundation 11. Lixte Biotechnology Holdings 12. Washington University Neurofibromatosis (NF) Center 13. NFCA Pittsburgh 14. Locus Genetics 15. The Children’s Tumour Foundation 16. Neurofibromatosis Midwest 17. Neurofibromatosis Northeast 18. Neurofibromatosis Michigan Frequently Asked Questions: 1. Which region has the largest share in Global Neurofibromatosis Treatment Market? Ans: Asia Pacific region held the highest share in 2022. 2. What is the growth rate of Global Neurofibromatosis Treatment Market? Ans: The Global market is growing at a CAGR of 13.3% during forecasting period 2023-2029. 3. What is scope of the Global Neurofibromatosis Treatment Market report? Ans: Global market report helps with the PESTEL, PORTER, COVID-19 Impact analysis, Recommendations for Investors & Leaders, and market estimation of the forecast period. 4. Who are the key players in Global Neurofibromatosis Treatment Market? Ans: The important key players in the Global market are – Erasmus Medical Center, GL Pharm Tech Corporation, University of Alabama at Birmingham, Assistance Publique - Hôpitaux de Paris, Indiana University, TATA Memorial Hospital (India), Apollo Hospitals (India), BLK Super Specialty Hospital, Fortis Hospitals, Texas Neurofibromatosis Foundation, Lixte Biotechnology Holdings, Washington University Neurofibromatosis (NF) Center, NFCA Pittsburgh, Locus Genetics, The Children’s Tumour Foundation, Neurofibromatosis Midwest, Neurofibromatosis Northeast, and Neurofibromatosis Michigan 5. What is the study period of this Market? Ans: The Global market is studied from 2022 to 2029.
1. Neurofibromatosis Treatment Market Introduction 1.1. Study Assumption and Market Definition 1.2. Scope of the Study 1.3. Executive Summary 2. Neurofibromatosis Treatment Market: Dynamics 2.1. Neurofibromatosis Treatment Market Trends by Region 2.1.1. North America Neurofibromatosis Treatment Market Trends 2.1.2. Europe Neurofibromatosis Treatment Market Trends 2.1.3. Asia Pacific Neurofibromatosis Treatment Market Trends 2.1.4. Middle East and Africa Neurofibromatosis Treatment Market Trends 2.1.5. South America Neurofibromatosis Treatment Market Trends 2.2. Neurofibromatosis Treatment Market Dynamics by Region 2.2.1. North America 2.2.1.1. North America Neurofibromatosis Treatment Market Drivers 2.2.1.2. North America Neurofibromatosis Treatment Market Restraints 2.2.1.3. North America Neurofibromatosis Treatment Market Opportunities 2.2.1.4. North America Neurofibromatosis Treatment Market Challenges 2.2.2. Europe 2.2.2.1. Europe Neurofibromatosis Treatment Market Drivers 2.2.2.2. Europe Neurofibromatosis Treatment Market Restraints 2.2.2.3. Europe Neurofibromatosis Treatment Market Opportunities 2.2.2.4. Europe Neurofibromatosis Treatment Market Challenges 2.2.3. Asia Pacific 2.2.3.1. Asia Pacific Neurofibromatosis Treatment Market Drivers 2.2.3.2. Asia Pacific Neurofibromatosis Treatment Market Restraints 2.2.3.3. Asia Pacific Neurofibromatosis Treatment Market Opportunities 2.2.3.4. Asia Pacific Neurofibromatosis Treatment Market Challenges 2.2.4. Middle East and Africa 2.2.4.1. Middle East and Africa Neurofibromatosis Treatment Market Drivers 2.2.4.2. Middle East and Africa Neurofibromatosis Treatment Market Restraints 2.2.4.3. Middle East and Africa Neurofibromatosis Treatment Market Opportunities 2.2.4.4. Middle East and Africa Neurofibromatosis Treatment Market Challenges 2.2.5. South America 2.2.5.1. South America Neurofibromatosis Treatment Market Drivers 2.2.5.2. South America Neurofibromatosis Treatment Market Restraints 2.2.5.3. South America Neurofibromatosis Treatment Market Opportunities 2.2.5.4. South America Neurofibromatosis Treatment Market Challenges 2.3. PORTER’s Five Forces Analysis 2.4. PESTLE Analysis 2.5. Technology Roadmap 2.6. Regulatory Landscape by Region 2.6.1. North America 2.6.2. Europe 2.6.3. Asia Pacific 2.6.4. Middle East and Africa 2.6.5. South America 2.7. Key Opinion Leader Analysis For Neurofibromatosis Treatment Industry 2.8. Analysis of Government Schemes and Initiatives For Neurofibromatosis Treatment Industry 2.9. Neurofibromatosis Treatment Market Trade Analysis 2.10. The Global Pandemic Impact on Neurofibromatosis Treatment Market 3. Neurofibromatosis Treatment Market: Global Market Size and Forecast by Segmentation by Demand and Supply Side (by Value in USD Million) 2022-2029 3.1. Neurofibromatosis Treatment Market Size and Forecast, by Type (2022-2029) 3.1.1. Neurofibromatosis 1 (NF1) 3.1.2. Neurofibromatosis 2 (NF2) 3.1.3. Schwannomatosis 3.2. Neurofibromatosis Treatment Market Size and Forecast, by Treatment (2022-2029) 3.2.1. Surgery 3.2.2. Focused radiation 3.2.3. Chemotherapy 3.3. Neurofibromatosis Treatment Market Size and Forecast, by End-Users (2022-2029) 3.3.1. Hospitals 3.3.2. Clinics 3.3.3. Others 3.4. Neurofibromatosis Treatment Market Size and Forecast, by Region (2022-2029) 3.4.1. North America 3.4.2. Europe 3.4.3. Asia Pacific 3.4.4. Middle East and Africa 3.4.5. South America 4. North America Neurofibromatosis Treatment Market Size and Forecast by Segmentation (by Value in USD Million) 2022-2029 4.1. North America Neurofibromatosis Treatment Market Size and Forecast, by Type (2022-2029) 4.1.1. Neurofibromatosis 1 (NF1) 4.1.2. Neurofibromatosis 2 (NF2) 4.1.3. Schwannomatosis 4.2. North America Neurofibromatosis Treatment Market Size and Forecast, by Treatment (2022-2029) 4.2.1. Surgery 4.2.2. Focused radiation 4.2.3. Chemotherapy 4.3. North America Neurofibromatosis Treatment Market Size and Forecast, by End-Users (2022-2029) 4.3.1. Hospitals 4.3.2. Clinics 4.3.3. Others 4.4. North America Neurofibromatosis Treatment Market Size and Forecast, by Country (2022-2029) 4.4.1. United States 4.4.1.1. United States Neurofibromatosis Treatment Market Size and Forecast, by Type (2022-2029) 4.4.1.1.1. Neurofibromatosis 1 (NF1) 4.4.1.1.2. Neurofibromatosis 2 (NF2) 4.4.1.1.3. Schwannomatosis 4.4.1.2. United States Neurofibromatosis Treatment Market Size and Forecast, by Treatment (2022-2029) 4.4.1.2.1. Surgery 4.4.1.2.2. Focused radiation 4.4.1.2.3. Chemotherapy 4.4.1.3. United States Neurofibromatosis Treatment Market Size and Forecast, by End-Users (2022-2029) 4.4.1.3.1. Hospitals 4.4.1.3.2. Clinics 4.4.1.3.3. Others 4.4.2. Canada 4.4.2.1. Canada Neurofibromatosis Treatment Market Size and Forecast, by Type (2022-2029) 4.4.2.1.1. Neurofibromatosis 1 (NF1) 4.4.2.1.2. Neurofibromatosis 2 (NF2) 4.4.2.1.3. Schwannomatosis 4.4.2.2. Canada Neurofibromatosis Treatment Market Size and Forecast, by Treatment (2022-2029) 4.4.2.2.1. Surgery 4.4.2.2.2. Focused radiation 4.4.2.2.3. Chemotherapy 4.4.2.3. Canada Neurofibromatosis Treatment Market Size and Forecast, by End-Users (2022-2029) 4.4.2.3.1. Hospitals 4.4.2.3.2. Clinics 4.4.2.3.3. Others 4.4.3. Mexico 4.4.3.1. Mexico Neurofibromatosis Treatment Market Size and Forecast, by Type (2022-2029) 4.4.3.1.1. Neurofibromatosis 1 (NF1) 4.4.3.1.2. Neurofibromatosis 2 (NF2) 4.4.3.1.3. Schwannomatosis 4.4.3.2. Mexico Neurofibromatosis Treatment Market Size and Forecast, by Treatment (2022-2029) 4.4.3.2.1. Surgery 4.4.3.2.2. Focused radiation 4.4.3.2.3. Chemotherapy 4.4.3.3. Mexico Neurofibromatosis Treatment Market Size and Forecast, by End-Users (2022-2029) 4.4.3.3.1. Hospitals 4.4.3.3.2. Clinics 4.4.3.3.3. Others 5. Europe Neurofibromatosis Treatment Market Size and Forecast by Segmentation (by Value in USD Million) 2022-2029 5.1. Europe Neurofibromatosis Treatment Market Size and Forecast, by Type (2022-2029) 5.2. Europe Neurofibromatosis Treatment Market Size and Forecast, by Treatment (2022-2029) 5.3. Europe Neurofibromatosis Treatment Market Size and Forecast, by End-Users (2022-2029) 5.4. Europe Neurofibromatosis Treatment Market Size and Forecast, by Country (2022-2029) 5.4.1. United Kingdom 5.4.1.1. United Kingdom Neurofibromatosis Treatment Market Size and Forecast, by Type (2022-2029) 5.4.1.2. United Kingdom Neurofibromatosis Treatment Market Size and Forecast, by Treatment (2022-2029) 5.4.1.3. United Kingdom Neurofibromatosis Treatment Market Size and Forecast, by End-Users(2022-2029) 5.4.2. France 5.4.2.1. France Neurofibromatosis Treatment Market Size and Forecast, by Type (2022-2029) 5.4.2.2. France Neurofibromatosis Treatment Market Size and Forecast, by Treatment (2022-2029) 5.4.2.3. France Neurofibromatosis Treatment Market Size and Forecast, by End-Users(2022-2029) 5.4.3. Germany 5.4.3.1. Germany Neurofibromatosis Treatment Market Size and Forecast, by Type (2022-2029) 5.4.3.2. Germany Neurofibromatosis Treatment Market Size and Forecast, by Treatment (2022-2029) 5.4.3.3. Germany Neurofibromatosis Treatment Market Size and Forecast, by End-Users (2022-2029) 5.4.4. Italy 5.4.4.1. Italy Neurofibromatosis Treatment Market Size and Forecast, by Type (2022-2029) 5.4.4.2. Italy Neurofibromatosis Treatment Market Size and Forecast, by Treatment (2022-2029) 5.4.4.3. Italy Neurofibromatosis Treatment Market Size and Forecast, by End-Users(2022-2029) 5.4.5. Spain 5.4.5.1. Spain Neurofibromatosis Treatment Market Size and Forecast, by Type (2022-2029) 5.4.5.2. Spain Neurofibromatosis Treatment Market Size and Forecast, by Treatment (2022-2029) 5.4.5.3. Spain Neurofibromatosis Treatment Market Size and Forecast, by End-Users (2022-2029) 5.4.6. Sweden 5.4.6.1. Sweden Neurofibromatosis Treatment Market Size and Forecast, by Type (2022-2029) 5.4.6.2. Sweden Neurofibromatosis Treatment Market Size and Forecast, by Treatment (2022-2029) 5.4.6.3. Sweden Neurofibromatosis Treatment Market Size and Forecast, by End-Users (2022-2029) 5.4.7. Austria 5.4.7.1. Austria Neurofibromatosis Treatment Market Size and Forecast, by Type (2022-2029) 5.4.7.2. Austria Neurofibromatosis Treatment Market Size and Forecast, by Treatment (2022-2029) 5.4.7.3. Austria Neurofibromatosis Treatment Market Size and Forecast, by End-Users (2022-2029) 5.4.8. Rest of Europe 5.4.8.1. Rest of Europe Neurofibromatosis Treatment Market Size and Forecast, by Type (2022-2029) 5.4.8.2. Rest of Europe Neurofibromatosis Treatment Market Size and Forecast, by Treatment (2022-2029) 5.4.8.3. Rest of Europe Neurofibromatosis Treatment Market Size and Forecast, by End-Users (2022-2029) 6. Asia Pacific Neurofibromatosis Treatment Market Size and Forecast by Segmentation (by Value in USD Million) 2022-2029 6.1. Asia Pacific Neurofibromatosis Treatment Market Size and Forecast, by Type (2022-2029) 6.2. Asia Pacific Neurofibromatosis Treatment Market Size and Forecast, by Treatment (2022-2029) 6.3. Asia Pacific Neurofibromatosis Treatment Market Size and Forecast, by End-Users (2022-2029) 6.4. Asia Pacific Neurofibromatosis Treatment Market Size and Forecast, by Country (2022-2029) 6.4.1. China 6.4.1.1. China Neurofibromatosis Treatment Market Size and Forecast, by Type (2022-2029) 6.4.1.2. China Neurofibromatosis Treatment Market Size and Forecast, by Treatment (2022-2029) 6.4.1.3. China Neurofibromatosis Treatment Market Size and Forecast, by End-Users (2022-2029) 6.4.2. S Korea 6.4.2.1. S Korea Neurofibromatosis Treatment Market Size and Forecast, by Type (2022-2029) 6.4.2.2. S Korea Neurofibromatosis Treatment Market Size and Forecast, by Treatment (2022-2029) 6.4.2.3. S Korea Neurofibromatosis Treatment Market Size and Forecast, by End-Users (2022-2029) 6.4.3. Japan 6.4.3.1. Japan Neurofibromatosis Treatment Market Size and Forecast, by Type (2022-2029) 6.4.3.2. Japan Neurofibromatosis Treatment Market Size and Forecast, by Treatment (2022-2029) 6.4.3.3. Japan Neurofibromatosis Treatment Market Size and Forecast, by End-Users (2022-2029) 6.4.4. India 6.4.4.1. India Neurofibromatosis Treatment Market Size and Forecast, by Type (2022-2029) 6.4.4.2. India Neurofibromatosis Treatment Market Size and Forecast, by Treatment (2022-2029) 6.4.4.3. India Neurofibromatosis Treatment Market Size and Forecast, by End-Users (2022-2029) 6.4.5. Australia 6.4.5.1. Australia Neurofibromatosis Treatment Market Size and Forecast, by Type (2022-2029) 6.4.5.2. Australia Neurofibromatosis Treatment Market Size and Forecast, by Treatment (2022-2029) 6.4.5.3. Australia Neurofibromatosis Treatment Market Size and Forecast, by End-Users (2022-2029) 6.4.6. Indonesia 6.4.6.1. Indonesia Neurofibromatosis Treatment Market Size and Forecast, by Type (2022-2029) 6.4.6.2. Indonesia Neurofibromatosis Treatment Market Size and Forecast, by Treatment (2022-2029) 6.4.6.3. Indonesia Neurofibromatosis Treatment Market Size and Forecast, by End-Users (2022-2029) 6.4.7. Malaysia 6.4.7.1. Malaysia Neurofibromatosis Treatment Market Size and Forecast, by Type (2022-2029) 6.4.7.2. Malaysia Neurofibromatosis Treatment Market Size and Forecast, by Treatment (2022-2029) 6.4.7.3. Malaysia Neurofibromatosis Treatment Market Size and Forecast, by End-Users (2022-2029) 6.4.8. Vietnam 6.4.8.1. Vietnam Neurofibromatosis Treatment Market Size and Forecast, by Type (2022-2029) 6.4.8.2. Vietnam Neurofibromatosis Treatment Market Size and Forecast, by Treatment (2022-2029) 6.4.8.3. Vietnam Neurofibromatosis Treatment Market Size and Forecast, by End-Users(2022-2029) 6.4.9. Taiwan 6.4.9.1. Taiwan Neurofibromatosis Treatment Market Size and Forecast, by Type (2022-2029) 6.4.9.2. Taiwan Neurofibromatosis Treatment Market Size and Forecast, by Treatment (2022-2029) 6.4.9.3. Taiwan Neurofibromatosis Treatment Market Size and Forecast, by End-Users (2022-2029) 6.4.10. Rest of Asia Pacific 6.4.10.1. Rest of Asia Pacific Neurofibromatosis Treatment Market Size and Forecast, by Type (2022-2029) 6.4.10.2. Rest of Asia Pacific Neurofibromatosis Treatment Market Size and Forecast, by Treatment (2022-2029) 6.4.10.3. Rest of Asia Pacific Neurofibromatosis Treatment Market Size and Forecast, by End-Users (2022-2029) 7. Middle East and Africa Neurofibromatosis Treatment Market Size and Forecast by Segmentation (by Value in USD Million) 2022-2029 7.1. Middle East and Africa Neurofibromatosis Treatment Market Size and Forecast, by Type (2022-2029) 7.2. Middle East and Africa Neurofibromatosis Treatment Market Size and Forecast, by Treatment (2022-2029) 7.3. Middle East and Africa Neurofibromatosis Treatment Market Size and Forecast, by End-Users (2022-2029) 7.4. Middle East and Africa Neurofibromatosis Treatment Market Size and Forecast, by Country (2022-2029) 7.4.1. South Africa 7.4.1.1. South Africa Neurofibromatosis Treatment Market Size and Forecast, by Type (2022-2029) 7.4.1.2. South Africa Neurofibromatosis Treatment Market Size and Forecast, by Treatment (2022-2029) 7.4.1.3. South Africa Neurofibromatosis Treatment Market Size and Forecast, by End-Users (2022-2029) 7.4.2. GCC 7.4.2.1. GCC Neurofibromatosis Treatment Market Size and Forecast, by Type (2022-2029) 7.4.2.2. GCC Neurofibromatosis Treatment Market Size and Forecast, by Treatment (2022-2029) 7.4.2.3. GCC Neurofibromatosis Treatment Market Size and Forecast, by End-Users (2022-2029) 7.4.3. Nigeria 7.4.3.1. Nigeria Neurofibromatosis Treatment Market Size and Forecast, by Type (2022-2029) 7.4.3.2. Nigeria Neurofibromatosis Treatment Market Size and Forecast, by Treatment (2022-2029) 7.4.3.3. Nigeria Neurofibromatosis Treatment Market Size and Forecast, by End-Users (2022-2029) 7.4.4. Rest of ME&A 7.4.4.1. Rest of ME&A Neurofibromatosis Treatment Market Size and Forecast, by Type (2022-2029) 7.4.4.2. Rest of ME&A Neurofibromatosis Treatment Market Size and Forecast, by Treatment (2022-2029) 7.4.4.3. Rest of ME&A Neurofibromatosis Treatment Market Size and Forecast, by End-Users (2022-2029) 8. South America Neurofibromatosis Treatment Market Size and Forecast by Segmentation (by Value in USD Million) 2022-2029 8.1. South America Neurofibromatosis Treatment Market Size and Forecast, by Type (2022-2029) 8.2. South America Neurofibromatosis Treatment Market Size and Forecast, by Treatment (2022-2029) 8.3. South America Neurofibromatosis Treatment Market Size and Forecast, by End-Users(2022-2029) 8.4. South America Neurofibromatosis Treatment Market Size and Forecast, by Country (2022-2029) 8.4.1. Brazil 8.4.1.1. Brazil Neurofibromatosis Treatment Market Size and Forecast, by Type (2022-2029) 8.4.1.2. Brazil Neurofibromatosis Treatment Market Size and Forecast, by Treatment (2022-2029) 8.4.1.3. Brazil Neurofibromatosis Treatment Market Size and Forecast, by End-Users (2022-2029) 8.4.2. Argentina 8.4.2.1. Argentina Neurofibromatosis Treatment Market Size and Forecast, by Type (2022-2029) 8.4.2.2. Argentina Neurofibromatosis Treatment Market Size and Forecast, by Treatment (2022-2029) 8.4.2.3. Argentina Neurofibromatosis Treatment Market Size and Forecast, by End-Users (2022-2029) 8.4.3. Rest Of South America 8.4.3.1. Rest Of South America Neurofibromatosis Treatment Market Size and Forecast, by Type (2022-2029) 8.4.3.2. Rest Of South America Neurofibromatosis Treatment Market Size and Forecast, by Treatment (2022-2029) 8.4.3.3. Rest Of South America Neurofibromatosis Treatment Market Size and Forecast, by End-Users (2022-2029) 9. Global Neurofibromatosis Treatment Market: Competitive Landscape 9.1. MMR Competition Matrix 9.2. Competitive Landscape 9.3. Key Players Benchmarking 9.3.1. Company Name 9.3.2. Business Segment 9.3.3. End-user Segment 9.3.4. Revenue (2022) 9.3.5. Company Locations 9.4. Leading Neurofibromatosis Treatment Market Companies, by market capitalization 9.5. Market Structure 9.5.1. Market Leaders 9.5.2. Market Followers 9.5.3. Emerging Players 9.6. Mergers and Acquisitions Details 10. Company Profile: Key Players 10.1. Erasmus Medical Center 10.1.1. Company Overview 10.1.2. Business Portfolio 10.1.3. Financial Overview 10.1.4. SWOT Analysis 10.1.5. Strategic Analysis 10.1.6. Scale of Operation (small, medium, and large) 10.1.7. Details on Partnership 10.1.8. Regulatory Accreditations and Certifications Received by Them 10.1.9. Awards Received by the Firm 10.1.10. Recent Developments 10.2. GL Pharm Tech Corporation 10.3. University of Alabama at Birmingham 10.4. Assistance Publique - Hôpitaux de Paris 10.5. Indiana University 10.6. TATA Memorial Hospital (India) 10.7. Apollo Hospitals (India) 10.8. BLK Super Specialty Hospital 10.9. Fortis Hospitals 10.10. Texas Neurofibromatosis Foundation 10.11. Lixte Biotechnology Holdings 10.12. Washington University Neurofibromatosis (NF) Center 10.13. NFCA Pittsburgh 10.14. Locus Genetics 10.15. The Children’s Tumour Foundation 10.16. Neurofibromatosis Midwest 10.17. Neurofibromatosis Northeast 10.18. Neurofibromatosis Michigan 11. Key Findings 12. Industry Recommendations 13. Neurofibromatosis Treatment Market: Research Methodology 14. Terms and Glossary
  • INQUIRE BEFORE BUYING